Authors: Mimura, Kosaku; Kua, Ley-Fang; Xiao, Jin-Fen; Asuncion, Bernadette Reyna; Nakayama, Yuko; Syn, Nicholas; Fazreen, Zul; Soong, Richie; Kono, Koji; Yong, Wei-Peng
Issue: Gastric Cancer . 2021 May;24(3):611-623.
Immunotherapy targeting PD-1 provides a limited survival benefit in patients with unresectable advanced or recurrent gastric cancer (GC). Beside PD-L1, the expression of inhibitory ligands such as CEACAM-1 and LSECtin on GC cells account for this limitation. Here we assessed their expression and immune suppressive effect in GC patients.